Suchergebnisse - "O3J8G9O825"

PubPharm (495)

1

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1 : week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

enthalten in: The lancet. HIV | 2024

von Orkin, C. | Molina, J. | Cahn, P. | +112

2

Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study) : an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial

enthalten in: The lancet. HIV | 2024

von Bekker, A. | Salvadori, N. | Rabie, H. | +10

ErratumIn: Lancet HIV. 2024 Apr 5;:. - PMID 38588690

3

Risk Factors for Incident Hypertension Within 1 Year of Initiating Antiretroviral Therapy Among People with HIV

enthalten in: AIDS research and human retroviruses | 2022

von Siddiqui, M. | Moore, T. | Long, D. | +6

4

A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania

enthalten in: Medical science monitor : international medical journal of experimental and clinical research | 2022

von Bacinschi, X. | Popescu, G. | Zgura, A. | +7

5

Improvement in Bioavailability and Pharmacokinetic Characteristics of Efavirenz with Booster Dose of Ritonavir in PEGylated PAMAM G4 Dendrimers

enthalten in: AAPS PharmSciTech | 2022

von Kharwade, R. | More, S. | Suresh, E. | +3

6

Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis

enthalten in: Therapeutic drug monitoring | 2022

von Huang, Y. | Huang, Y. | Wu, T. | +4

7

Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2022

von Heaton, B. | Jensen, R. | Line, J. | +4

8

Glycemic Control in Patients Undergoing Treatment With Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir for Chronic Hepatitis C Infection

enthalten in: In vivo (Athens, Greece) | 2022

von Bacinschi, X. | Mercan-Stanciu, A. | Toma, L. | +6

9

hsa-miR-17-5p : A Possible Predictor of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin Therapy Efficacy in Hepatitis C Infection

enthalten in: Current microbiology | 2022

von Öksüz, Z. | Üçbilek, E. | Serin, M. | +3

10

Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders

enthalten in: The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology | 2022

von Sonsuz, A. | Bozcan, S. | Hatemi, �. | +5

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[50]